Landec Corporation Schedules First Quarter 2014 Earnings Release for September 24, 2013 and Conference Call for September 25, 2013

company logo

MENLO PARK, Calif., Sept. 3, 2013 (GLOBE NEWSWIRE) -- Landec Corporation (Nasdaq:LNDC) announced today that it will report financial results for the fiscal year 2014 first quarter ended August 25, 2013, after market close on September 24, 2013.

The news release will be followed the next morning, Wednesday, September 25, 2013, by a teleconference and webcast open to all interested parties at 8:00 a.m., Pacific Time. The teleconference can be accessed by calling 866-793-1301 or 703-639-1307. Please log in 5-10 minutes prior to the beginning of the call.

This call is being webcast and can be accessed on Landec's web site at www.Landec.com/earningscall. The webcast will be available for 30 days through October 25, 2013. A replay of the teleconference will be available for one week until midnight Eastern Time, Wednesday, October 2, 2013, by calling 888-266-2081 or 703-925-2533. The access code for the replay is 1621865.

For further information, please call Greg Skinner (650) 261-3677.

Landec Corporation is a materials science company that leverages its proprietary polymer technologies, application development and innovation capabilities to develop and commercialize new products in food and biomaterials markets. Landec's subsidiary, Apio, has become the leader in US fresh-cut specialty packaged vegetables sold in North America based on combining Landec's proprietary food packaging technology and the strength of two major national brands, Eat Smart® and GreenLine®, with the capabilities of large scale processing and national distribution. Lifecore Biomedical, a subsidiary of Landec, is a premium supplier of hyaluronan-based materials and medical products to ophthalmic, orthopedic and veterinary markets worldwide. In addition, Lifecore Biomedical provides specialized aseptic fill and finish services in a cGMP validated manufacturing facility for supplying commercial, clinical and pre-clinical products. Landec will also periodically work with market-leading companies to develop and commercialize differentiated polymer-based products under R&D and royalty agreements. For more information about the Company, visit Landec's website at www.landec.com.

CONTACT: Landec Corporation Greg Skinner 650-261-3677 Investor Relations Contact: Liolios Group, Inc. Justin Vaicek 949-574-3860 LNDC@liolios.com

Source:Landec Corporation